TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07402915: An Open-label, Fixed Sequence Phase I Study to Evaluate the Effect of Itraconazole (a Strong CYP3A Inhibitor) on the Pharmacokinetics of AZ14170132, the TOP1 Inhibitor Payload of the Antibody Drug Conjugate AZD5335, in P

Sponsor: AstraZeneca · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 32 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$816,816

Rescue Site Savings

+$534,072

Unlock Full NCT07402915 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07402915 Rescue Dossier →